Comparative Pharmacology
Head-to-head clinical analysis: LODINE XL versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE XL versus MECLOFENAMATE SODIUM.
LODINE XL vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
400 mg or 600 mg orally once daily.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category C
Category C
NSAID
NSAID